These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8877730)

  • 1. Repression of interleukin-2 and interleukin-4 promoters by tumor suppressor protein p53.
    Pesch J; Brehm U; Staib C; Grummt F
    J Interferon Cytokine Res; 1996 Aug; 16(8):595-600. PubMed ID: 8877730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product.
    Santhanam U; Ray A; Sehgal PB
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7605-9. PubMed ID: 1652755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG I(Y) interferes with the DNA binding of NF-AT factors and the induction of the interleukin 4 promoter in T cells.
    Klein-Hessling S; Schneider G; Heinfling A; Chuvpilo S; Serfling E
    Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15311-6. PubMed ID: 8986808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The catalytic domain of pp56(lck), but not its regulatory domain, is sufficient for inducing IL-2 production.
    Carrera AC; Calvo V; Borlado LR; Paradis H; Alemany S; Roberts TM; Martinez-A C
    J Immunol; 1996 Nov; 157(9):3775-82. PubMed ID: 8892605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth.
    Pellegata NS; Cajot JF; Stanbridge EJ
    Oncogene; 1995 Jul; 11(2):337-49. PubMed ID: 7624148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions.
    Subler MA; Martin DW; Deb S
    Oncogene; 1994 May; 9(5):1351-9. PubMed ID: 8152795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif.
    Ragimov N; Krauskopf A; Navot N; Rotter V; Oren M; Aloni Y
    Oncogene; 1993 May; 8(5):1183-93. PubMed ID: 8479742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal requirements for interleukin 4 promoter activation in human T cells.
    Paliogianni F; Hama N; Mavrothalassitis GJ; Thyphronitis G; Boumpas DT
    Cell Immunol; 1996 Feb; 168(1):33-8. PubMed ID: 8599837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-4 gene transcription in human T cells is suppressed by T-bet.
    Kitamura N; Kitamura F; Kaminuma O; Miyatake S; Tatsumi H; Nemoto S; Mori A
    Int Arch Allergy Immunol; 2007; 143 Suppl 1():68-70. PubMed ID: 17541280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of Tax-activated human Jurkat leukemia T cells by all-trans retinoic acid requires JNK-1 inhibition.
    Parra E; Gutiérrez L
    Oncol Rep; 2013 Jan; 29(1):387-93. PubMed ID: 23129057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th2-specific protein/DNA interactions at the proximal nuclear factor-AT site contribute to the functional activity of the human IL-4 promoter.
    Li-Weber M; Salgame P; Hu C; Davydov IV; Laur O; Klevenz S; Krammer PH
    J Immunol; 1998 Aug; 161(3):1380-9. PubMed ID: 9686601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.
    Angelo LS; Talpaz M; Kurzrock R
    Cancer Res; 2002 Feb; 62(3):932-40. PubMed ID: 11830554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.
    Wang Q; Beck WT
    Cancer Res; 1998 Dec; 58(24):5762-9. PubMed ID: 9865734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of high-mobility group I(Y) proteins in expression of IL-2 and T cell proliferation.
    Himes SR; Reeves R; Attema J; Nissen M; Li Y; Shannon MF
    J Immunol; 2000 Mar; 164(6):3157-68. PubMed ID: 10706706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple signals are required for function of the human granulocyte-macrophage colony-stimulating factor gene promoter in T cells.
    Jenkins F; Cockerill PN; Bohmann D; Shannon MF
    J Immunol; 1995 Aug; 155(3):1240-51. PubMed ID: 7636192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of nuclear factor of activated T-cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells.
    Yea SS; Yang KH; Kaminski NE
    J Pharmacol Exp Ther; 2000 Feb; 292(2):597-605. PubMed ID: 10640296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ETS1 in IL-2 gene expression.
    Romano-Spica V; Georgiou P; Suzuki H; Papas TS; Bhat NK
    J Immunol; 1995 Mar; 154(6):2724-32. PubMed ID: 7876544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line.
    Wang Y; Ramqvist T; Szekely L; Axelson H; Klein G; Wiman KG
    Cell Growth Differ; 1993 Jun; 4(6):467-73. PubMed ID: 8373731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin activates transcription from the GM-CSF promoter in synergy with either protein kinase C or NF-kappa B/AP-1 in T cells.
    Tsuboi A; Muramatsu M; Tsutsumi A; Arai K; Arai N
    Biochem Biophys Res Commun; 1994 Mar; 199(2):1064-72. PubMed ID: 8135780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
    Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
    Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.